TTP 399

Drug Profile

TTP 399

Alternative Names: GK1-399; TTP-399

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 01 Sep 2016 vTv Therapeutics completes a phase II trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA (PO) (NCT02405260)
  • 14 Jun 2016 Clinical trials in Type-2 diabetes mellitus (Treatment-naive) in USA before June 2016 (PO)
  • 14 Jun 2016 Interim efficacy data from a 10-day pilot trial in Type-2 diabetes mellitus (treatment-naive) presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top